Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Pharmaceuticals has announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application directed towards the company's CP024 intranasal growth hormone and CP046 intranasal teriparatide (parathyroid hormone 1-34) products formulated using its proprietary CriticalSorb drug delivery technology.
Subscribe to our email newsletter
The patent application allowed by the USPTO (application number 13/063,411) relates to pharmaceutical compositions of growth hormone or parathyroid hormone and the CriticalSorb™ absorption enhancer in a form suitable for administration to the nasal, buccal and / or respiratory tract.
Similar patent protection has already been obtained in Russia, Singapore and New Zealand with pending patents in other major territories including Europe and Japan. Together the market for growth hormone and parathyroid hormone products is in excess of $4bn per annum with strong interest in alternatives to the current daily injectable products.
Critical Pharmaceuticals CEO Dr Gareth King noted that the allowance of a US patent further strengthens the data package on our CP024 nasal growth hormone product that has demonstrated strong biological activity in Phase I clinical trials.
"It will provide important protection to future license partners for the continued development and commercialisation of CP024 and CP046 intranasal teriparatide products," King added.
The allowed applications are part of Critical Pharmaceuticals broader capability and intellectual property in advanced drug delivery and formulation technology for challenging molecules such as peptide, protein and antibody drugs.
The CriticalSorb technology was developed by Critical Pharmaceuticals scientists in Nottingham, UK.